Mobile

A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-001657-41

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of the study are to: • Assess the safety profile and pharmacokinetics (PK) of venetoclax in combination with azacitidine • Determine the recommended dose (RD) and dosing schedule of venetoclax in combination with azacitidine • Determine the overall response rate of venetoclax in combination with azacitidine and of azacitidine monotherapy

Critère d'inclusion

  • Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Liens